116
Participants
Start Date
May 5, 2016
Primary Completion Date
April 14, 2022
Study Completion Date
April 14, 2022
INCB059872
"Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth."
all-trans retinoic acid (ATRA)
azacitidine
nivolumab
Columbia University, New York
Roswell Park Cancer Institute, Buffalo
University of Pennsylvania, Philadelphia
University of Alabama, Birmingham
Vanderbilt University, Nashville
Northwestern University, Chicago
University of Kansas Center for Research, Inc., Kansas City
University of Texas MD Anderson Cancer Center, Houston
UCLA Medical Center, Los Angeles
Moores UCSD Cancer Center, La Jolla
Oregon Health Science University, Portland
Institut Jules Bordet, Brussels
Netherland Cancer Institute, Amsterdam
VU Medical Center, Amsterdam
Erasmus MC, Rotterdam
Lead Sponsor
Incyte Corporation
INDUSTRY